Atopic Dermatitis and Rosacea Exhibit Unexpected Convergences in Pathogenesis and Comorbidities
Background
Traditionally, Atopic Dermatitis (AD) and rosacea have been viewed as distinct inflammatory skin disorders with separate pathophysiologies. AD is characterized by immune dysregulation, skin barrier dysfunction, and pruritus, often involving the JAK/STAT signaling pathway. Rosacea, conversely, is known for neurovascular dysregulation and innate immune activation. However, emerging evidence suggests surprising convergences in clinical manifestations, comorbidity profiles, and underlying pathogenic mechanisms, prompting a critical re-evaluation of whether these conditions share common upstream drivers or merely exhibit parallel, non-specific immune responses.
Study Design
Researchers conducted a comprehensive literature review across PubMed, Embase, Scopus, and the Cochrane Library from April 2016 to April 2026. The search strategy combined controlled vocabulary and free-text terms such as "rosacea", "atopic dermatitis", "mast cells", "comorbidity", "microbiome", "innate immunity", "adaptive immunity", and "neurovascular". Included studies focused on AD and/or rosacea, investigating relevant immunological mechanisms, comorbidities, or pathophysiological pathways with sufficient data for qualitative synthesis. Both original research and high-quality reviews/meta-analyses were considered, while duplicates or studies lacking methodological detail were excluded.
Results
The review identified significant convergences between atopic dermatitis and rosacea across multiple domains, challenging their traditional classification as entirely distinct conditions. Mechanistically, both disorders show evidence of shared dysregulation in innate immunity, adaptive immunity, and neurovascular pathways. For instance, both conditions involve mast cell activation and altered neuropeptide signaling. Furthermore, the skin microbiome and gut microbiome appear to play roles in both, with dysbiosis contributing to chronic inflammation and oxidative stress, potentially mediated by short-chain fatty acids. Genetic predispositions and environmental triggers also exhibit overlaps. > The most striking finding is the shared dysregulation in immune responses and neurovascular pathways, suggesting common upstream drivers rather than merely parallel, non-specific immune activation. This includes altered TLR signaling and cathelicidin expression in both, alongside disruptions in the skin barrier function. The review also highlighted shared comorbidities, indicating systemic connections beyond the skin.
Key Findings
- AD and rosacea exhibit convergences in clinical manifestations and comorbidity profiles.
- Shared pathogenic mechanisms include dysregulation of innate and adaptive immunity.
- Both conditions show altered neurovascular pathways and mast cell activation.
- The skin and gut microbiomes contribute to the pathogenesis of both AD and rosacea.
- Mechanistic overlaps suggest potential for shared therapeutic strategies targeting common upstream drivers.
Why It Matters
Understanding the mechanistic overlaps between atopic dermatitis and rosacea could revolutionize therapeutic strategies, moving beyond disease-specific treatments towards shared, mechanism-targeted interventions. This convergence suggests that treatments targeting common pathways, such as immune modulation or microbiome restoration, might be effective for both conditions. For peptide users and biohackers, this opens avenues for exploring compounds that influence shared immune or neurovascular pathways, or those that support a healthy microbiome, potentially impacting both skin conditions. The review underscores the need for further research to confirm true mechanistic overlap, which could lead to novel, dual-purpose protocols and more holistic approaches to managing chronic inflammatory skin diseases.
atopic-dermatitis
rosacea
skin-disorders
inflammation
immunology
microbiome